Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-560.85%
operating margin TTM
-633.04%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -6.49 |
| peg ratio | 0.79 |
| price to book ratio | 2.48 |
| price to sales ratio | 41.62 |
| enterprise value multiple | -8.01 |
| price fair value | 2.48 |
profitability ratios | |
|---|---|
| gross profit margin | 92.94% |
| operating profit margin | -633.04% |
| pretax profit margin | -570.8% |
| net profit margin | -560.85% |
| return on assets | -23.15% |
| return on equity | -43.31% |
| return on capital employed | -28.9% |
liquidity ratios | |
|---|---|
| current ratio | 9.52 |
| quick ratio | 9.52 |
| cash ratio | 1.35 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 125.03 |
| days of payables outstanding | 1,286.58 |
| cash conversion cycle | -1,161.56 |
| receivables turnover | 2.92 |
| payables turnover | 0.28 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.05 |
| debt equity ratio | 0.08 |
| long term debt to capitalization | 0.06 |
| total debt to capitalization | 0.07 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -1.62 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.84 |
| cash per share | 7.29 |
| operating cash flow per share | -0.72 |
| free cash flow operating cash flow ratio | 1.16 |
| cash flow coverage ratios | -1.62 |
| short term coverage ratios | -13.27 |
| capital expenditure coverage ratio | -6.22 |
Frequently Asked Questions
When was the last time Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported earnings?
Monte Rosa Therapeutics, Inc. (GLUE) published its most recent earnings results on 06-08-2026.
What is Monte Rosa Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)'s trailing twelve months ROE is -43.31%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Monte Rosa Therapeutics, Inc. (GLUE) currently has a ROA of -23.15%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did GLUE's net profit margin stand at?
GLUE reported a profit margin of -560.85% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is GLUE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 9.52 in the most recent quarter. The quick ratio stood at 9.52, with a Debt/Eq ratio of 0.08.